nodes	percent_of_prediction	percent_of_DWPC	metapath
Mepivacaine—SCN5A—dilated cardiomyopathy	0.783	1	CbGaD
Mepivacaine—SCN5A—purkinje fiber—dilated cardiomyopathy	0.0446	0.453	CbGeAlD
Mepivacaine—SCN5A—endocardium—dilated cardiomyopathy	0.023	0.234	CbGeAlD
Mepivacaine—SCN5A—sinoatrial node—dilated cardiomyopathy	0.0218	0.221	CbGeAlD
Mepivacaine—SCN8A—Interaction between L1 and Ankyrins—SCN5A—dilated cardiomyopathy	0.00605	0.0702	CbGpPWpGaD
Mepivacaine—SCN9A—Interaction between L1 and Ankyrins—SCN5A—dilated cardiomyopathy	0.00489	0.0568	CbGpPWpGaD
Mepivacaine—SCN3A—Interaction between L1 and Ankyrins—SCN5A—dilated cardiomyopathy	0.00468	0.0543	CbGpPWpGaD
Mepivacaine—SCN2A—Interaction between L1 and Ankyrins—SCN5A—dilated cardiomyopathy	0.0045	0.0522	CbGpPWpGaD
Mepivacaine—SCN4A—Interaction between L1 and Ankyrins—SCN5A—dilated cardiomyopathy	0.0045	0.0522	CbGpPWpGaD
Mepivacaine—SCN1A—Interaction between L1 and Ankyrins—SCN5A—dilated cardiomyopathy	0.00434	0.0503	CbGpPWpGaD
Mepivacaine—SCN10A—Interaction between L1 and Ankyrins—SCN5A—dilated cardiomyopathy	0.00434	0.0503	CbGpPWpGaD
Mepivacaine—SCN8A—L1CAM interactions—SCN5A—dilated cardiomyopathy	0.00232	0.0269	CbGpPWpGaD
Mepivacaine—SCN5A—cardiac ventricle—dilated cardiomyopathy	0.00193	0.0197	CbGeAlD
Mepivacaine—SCN5A—Cardiac Progenitor Differentiation—MYH6—dilated cardiomyopathy	0.00188	0.0218	CbGpPWpGaD
Mepivacaine—SCN9A—L1CAM interactions—SCN5A—dilated cardiomyopathy	0.00188	0.0218	CbGpPWpGaD
Mepivacaine—Ropivacaine—SCN5A—dilated cardiomyopathy	0.00186	0.29	CrCbGaD
Mepivacaine—SCN5A—myocardium—dilated cardiomyopathy	0.00182	0.0185	CbGeAlD
Mepivacaine—SCN3A—L1CAM interactions—SCN5A—dilated cardiomyopathy	0.0018	0.0208	CbGpPWpGaD
Mepivacaine—Tocainide—SCN5A—dilated cardiomyopathy	0.00175	0.273	CrCbGaD
Mepivacaine—SCN4A—L1CAM interactions—SCN5A—dilated cardiomyopathy	0.00173	0.02	CbGpPWpGaD
Mepivacaine—SCN2A—L1CAM interactions—SCN5A—dilated cardiomyopathy	0.00173	0.02	CbGpPWpGaD
Mepivacaine—SCN5A—Cardiac Progenitor Differentiation—TNNI3—dilated cardiomyopathy	0.00168	0.0195	CbGpPWpGaD
Mepivacaine—SCN1A—L1CAM interactions—SCN5A—dilated cardiomyopathy	0.00166	0.0193	CbGpPWpGaD
Mepivacaine—SCN10A—L1CAM interactions—SCN5A—dilated cardiomyopathy	0.00166	0.0193	CbGpPWpGaD
Mepivacaine—SCN4A—heart—dilated cardiomyopathy	0.00164	0.0166	CbGeAlD
Mepivacaine—SCN5A—Cardiac Progenitor Differentiation—ACTC1—dilated cardiomyopathy	0.00143	0.0165	CbGpPWpGaD
Mepivacaine—SCN5A—Cardiac Progenitor Differentiation—TNNT2—dilated cardiomyopathy	0.00143	0.0165	CbGpPWpGaD
Mepivacaine—Lidocaine—SCN5A—dilated cardiomyopathy	0.00135	0.211	CrCbGaD
Mepivacaine—SCN3A—heart—dilated cardiomyopathy	0.00127	0.0129	CbGeAlD
Mepivacaine—SCN5A—heart—dilated cardiomyopathy	0.00127	0.0129	CbGeAlD
Mepivacaine—Laryngeal oedema—Lisinopril—dilated cardiomyopathy	0.00118	0.0446	CcSEcCtD
Mepivacaine—SCN5A—cardiac atrium—dilated cardiomyopathy	0.00109	0.011	CbGeAlD
Mepivacaine—Drowsiness—Spironolactone—dilated cardiomyopathy	0.00103	0.0392	CcSEcCtD
Mepivacaine—SCN8A—Axon guidance—SCN5A—dilated cardiomyopathy	0.000878	0.0102	CbGpPWpGaD
Mepivacaine—Swelling—Furosemide—dilated cardiomyopathy	0.000828	0.0314	CcSEcCtD
Mepivacaine—SCN8A—Developmental Biology—ZIC3—dilated cardiomyopathy	0.000826	0.00959	CbGpPWpGaD
Mepivacaine—Lidocaine—SLC22A5—dilated cardiomyopathy	0.000779	0.121	CrCbGaD
Mepivacaine—Anaphylactoid reaction—Furosemide—dilated cardiomyopathy	0.000755	0.0286	CcSEcCtD
Mepivacaine—SCN9A—Axon guidance—SCN5A—dilated cardiomyopathy	0.00071	0.00824	CbGpPWpGaD
Mepivacaine—Urinary retention—Furosemide—dilated cardiomyopathy	0.000695	0.0263	CcSEcCtD
Mepivacaine—SCN3A—Axon guidance—SCN5A—dilated cardiomyopathy	0.000679	0.00788	CbGpPWpGaD
Mepivacaine—Lidocaine—EGFR—dilated cardiomyopathy	0.000678	0.106	CrCbGaD
Mepivacaine—SCN9A—Developmental Biology—ZIC3—dilated cardiomyopathy	0.000668	0.00775	CbGpPWpGaD
Mepivacaine—Anaphylactic shock—Spironolactone—dilated cardiomyopathy	0.00066	0.025	CcSEcCtD
Mepivacaine—SCN2A—Axon guidance—SCN5A—dilated cardiomyopathy	0.000652	0.00757	CbGpPWpGaD
Mepivacaine—SCN4A—Axon guidance—SCN5A—dilated cardiomyopathy	0.000652	0.00757	CbGpPWpGaD
Mepivacaine—SCN3A—Developmental Biology—ZIC3—dilated cardiomyopathy	0.000639	0.00742	CbGpPWpGaD
Mepivacaine—SCN1A—Axon guidance—SCN5A—dilated cardiomyopathy	0.000629	0.0073	CbGpPWpGaD
Mepivacaine—SCN10A—Axon guidance—SCN5A—dilated cardiomyopathy	0.000629	0.0073	CbGpPWpGaD
Mepivacaine—SCN8A—Developmental Biology—SCN5A—dilated cardiomyopathy	0.000626	0.00727	CbGpPWpGaD
Mepivacaine—SCN4A—Developmental Biology—ZIC3—dilated cardiomyopathy	0.000614	0.00713	CbGpPWpGaD
Mepivacaine—SCN2A—Developmental Biology—ZIC3—dilated cardiomyopathy	0.000614	0.00713	CbGpPWpGaD
Mepivacaine—SCN8A—L1CAM interactions—ITGB1—dilated cardiomyopathy	0.000612	0.00711	CbGpPWpGaD
Mepivacaine—SCN10A—Developmental Biology—ZIC3—dilated cardiomyopathy	0.000592	0.00687	CbGpPWpGaD
Mepivacaine—SCN1A—Developmental Biology—ZIC3—dilated cardiomyopathy	0.000592	0.00687	CbGpPWpGaD
Mepivacaine—Somnolence—Spironolactone—dilated cardiomyopathy	0.000587	0.0222	CcSEcCtD
Mepivacaine—Anaphylactoid reaction—Lisinopril—dilated cardiomyopathy	0.000566	0.0215	CcSEcCtD
Mepivacaine—SCN5A—SIDS Susceptibility Pathways—RYR2—dilated cardiomyopathy	0.000565	0.00656	CbGpPWpGaD
Mepivacaine—Drowsiness—Furosemide—dilated cardiomyopathy	0.000563	0.0213	CcSEcCtD
Mepivacaine—Sweating—Furosemide—dilated cardiomyopathy	0.00054	0.0205	CcSEcCtD
Mepivacaine—Urticaria—Spironolactone—dilated cardiomyopathy	0.000524	0.0199	CcSEcCtD
Mepivacaine—Body temperature increased—Spironolactone—dilated cardiomyopathy	0.000522	0.0198	CcSEcCtD
Mepivacaine—Cardiac arrest—Lisinopril—dilated cardiomyopathy	0.000521	0.0198	CcSEcCtD
Mepivacaine—SCN9A—Developmental Biology—SCN5A—dilated cardiomyopathy	0.000506	0.00588	CbGpPWpGaD
Mepivacaine—SCN9A—L1CAM interactions—ITGB1—dilated cardiomyopathy	0.000495	0.00575	CbGpPWpGaD
Mepivacaine—SCN8A—L1CAM interactions—RAC1—dilated cardiomyopathy	0.000492	0.00571	CbGpPWpGaD
Mepivacaine—Hypersensitivity—Spironolactone—dilated cardiomyopathy	0.000486	0.0184	CcSEcCtD
Mepivacaine—SCN3A—Developmental Biology—SCN5A—dilated cardiomyopathy	0.000484	0.00562	CbGpPWpGaD
Mepivacaine—SCN3A—L1CAM interactions—ITGB1—dilated cardiomyopathy	0.000474	0.0055	CbGpPWpGaD
Mepivacaine—Tinnitus—Furosemide—dilated cardiomyopathy	0.000471	0.0179	CcSEcCtD
Mepivacaine—Pruritus—Spironolactone—dilated cardiomyopathy	0.000467	0.0177	CcSEcCtD
Mepivacaine—SCN4A—Developmental Biology—SCN5A—dilated cardiomyopathy	0.000465	0.0054	CbGpPWpGaD
Mepivacaine—SCN2A—Developmental Biology—SCN5A—dilated cardiomyopathy	0.000465	0.0054	CbGpPWpGaD
Mepivacaine—Sweating increased—Lisinopril—dilated cardiomyopathy	0.000462	0.0175	CcSEcCtD
Mepivacaine—SCN2A—L1CAM interactions—ITGB1—dilated cardiomyopathy	0.000455	0.00528	CbGpPWpGaD
Mepivacaine—SCN4A—L1CAM interactions—ITGB1—dilated cardiomyopathy	0.000455	0.00528	CbGpPWpGaD
Mepivacaine—SCN10A—Developmental Biology—SCN5A—dilated cardiomyopathy	0.000449	0.00521	CbGpPWpGaD
Mepivacaine—SCN1A—Developmental Biology—SCN5A—dilated cardiomyopathy	0.000449	0.00521	CbGpPWpGaD
Mepivacaine—Erythema—Furosemide—dilated cardiomyopathy	0.00044	0.0167	CcSEcCtD
Mepivacaine—SCN10A—L1CAM interactions—ITGB1—dilated cardiomyopathy	0.000439	0.00509	CbGpPWpGaD
Mepivacaine—SCN1A—L1CAM interactions—ITGB1—dilated cardiomyopathy	0.000439	0.00509	CbGpPWpGaD
Mepivacaine—Dizziness—Spironolactone—dilated cardiomyopathy	0.000436	0.0165	CcSEcCtD
Mepivacaine—Vomiting—Spironolactone—dilated cardiomyopathy	0.00042	0.0159	CcSEcCtD
Mepivacaine—SCN5A—Developmental Biology—ZIC3—dilated cardiomyopathy	0.000416	0.00483	CbGpPWpGaD
Mepivacaine—Vision blurred—Furosemide—dilated cardiomyopathy	0.000415	0.0157	CcSEcCtD
Mepivacaine—Headache—Spironolactone—dilated cardiomyopathy	0.000414	0.0157	CcSEcCtD
Mepivacaine—Sweating—Lisinopril—dilated cardiomyopathy	0.000405	0.0154	CcSEcCtD
Mepivacaine—Agitation—Furosemide—dilated cardiomyopathy	0.000404	0.0153	CcSEcCtD
Mepivacaine—SCN9A—L1CAM interactions—RAC1—dilated cardiomyopathy	0.000398	0.00462	CbGpPWpGaD
Mepivacaine—Nausea—Spironolactone—dilated cardiomyopathy	0.000392	0.0149	CcSEcCtD
Mepivacaine—Bradycardia—Lisinopril—dilated cardiomyopathy	0.000386	0.0146	CcSEcCtD
Mepivacaine—SCN3A—L1CAM interactions—RAC1—dilated cardiomyopathy	0.000381	0.00442	CbGpPWpGaD
Mepivacaine—SCN8A—Axon guidance—PSEN2—dilated cardiomyopathy	0.00037	0.00429	CbGpPWpGaD
Mepivacaine—SCN2A—L1CAM interactions—RAC1—dilated cardiomyopathy	0.000366	0.00425	CbGpPWpGaD
Mepivacaine—SCN4A—L1CAM interactions—RAC1—dilated cardiomyopathy	0.000366	0.00425	CbGpPWpGaD
Mepivacaine—Anaphylactic shock—Furosemide—dilated cardiomyopathy	0.000359	0.0136	CcSEcCtD
Mepivacaine—Tinnitus—Lisinopril—dilated cardiomyopathy	0.000354	0.0134	CcSEcCtD
Mepivacaine—Shock—Furosemide—dilated cardiomyopathy	0.000353	0.0134	CcSEcCtD
Mepivacaine—SCN10A—L1CAM interactions—RAC1—dilated cardiomyopathy	0.000353	0.00409	CbGpPWpGaD
Mepivacaine—SCN1A—L1CAM interactions—RAC1—dilated cardiomyopathy	0.000353	0.00409	CbGpPWpGaD
Mepivacaine—Hyperhidrosis—Furosemide—dilated cardiomyopathy	0.000347	0.0132	CcSEcCtD
Mepivacaine—Chills—Lisinopril—dilated cardiomyopathy	0.00034	0.0129	CcSEcCtD
Mepivacaine—Hypotension—Furosemide—dilated cardiomyopathy	0.000336	0.0127	CcSEcCtD
Mepivacaine—Erythema—Lisinopril—dilated cardiomyopathy	0.00033	0.0125	CcSEcCtD
Mepivacaine—Tension—Lisinopril—dilated cardiomyopathy	0.000324	0.0123	CcSEcCtD
Mepivacaine—Paraesthesia—Furosemide—dilated cardiomyopathy	0.000322	0.0122	CcSEcCtD
Mepivacaine—Nervousness—Lisinopril—dilated cardiomyopathy	0.000321	0.0122	CcSEcCtD
Mepivacaine—Back pain—Lisinopril—dilated cardiomyopathy	0.000319	0.0121	CcSEcCtD
Mepivacaine—Somnolence—Furosemide—dilated cardiomyopathy	0.000319	0.0121	CcSEcCtD
Mepivacaine—Vision blurred—Lisinopril—dilated cardiomyopathy	0.000311	0.0118	CcSEcCtD
Mepivacaine—Tremor—Lisinopril—dilated cardiomyopathy	0.000309	0.0117	CcSEcCtD
Mepivacaine—SCN5A—L1CAM interactions—ITGB1—dilated cardiomyopathy	0.000309	0.00358	CbGpPWpGaD
Mepivacaine—Angioedema—Lisinopril—dilated cardiomyopathy	0.000302	0.0114	CcSEcCtD
Mepivacaine—SCN9A—Axon guidance—PSEN2—dilated cardiomyopathy	0.000299	0.00347	CbGpPWpGaD
Mepivacaine—Syncope—Lisinopril—dilated cardiomyopathy	0.000296	0.0112	CcSEcCtD
Mepivacaine—Loss of consciousness—Lisinopril—dilated cardiomyopathy	0.00029	0.011	CcSEcCtD
Mepivacaine—SCN3A—Axon guidance—PSEN2—dilated cardiomyopathy	0.000286	0.00332	CbGpPWpGaD
Mepivacaine—Urticaria—Furosemide—dilated cardiomyopathy	0.000285	0.0108	CcSEcCtD
Mepivacaine—Body temperature increased—Furosemide—dilated cardiomyopathy	0.000284	0.0108	CcSEcCtD
Mepivacaine—Anxiety—Lisinopril—dilated cardiomyopathy	0.00028	0.0106	CcSEcCtD
Mepivacaine—SCN4A—Axon guidance—PSEN2—dilated cardiomyopathy	0.000275	0.00319	CbGpPWpGaD
Mepivacaine—SCN2A—Axon guidance—PSEN2—dilated cardiomyopathy	0.000275	0.00319	CbGpPWpGaD
Mepivacaine—Anaphylactic shock—Lisinopril—dilated cardiomyopathy	0.000269	0.0102	CcSEcCtD
Mepivacaine—Oedema—Lisinopril—dilated cardiomyopathy	0.000269	0.0102	CcSEcCtD
Mepivacaine—SCN10A—Axon guidance—PSEN2—dilated cardiomyopathy	0.000265	0.00308	CbGpPWpGaD
Mepivacaine—SCN1A—Axon guidance—PSEN2—dilated cardiomyopathy	0.000265	0.00308	CbGpPWpGaD
Mepivacaine—Shock—Lisinopril—dilated cardiomyopathy	0.000265	0.01	CcSEcCtD
Mepivacaine—Hypersensitivity—Furosemide—dilated cardiomyopathy	0.000265	0.01	CcSEcCtD
Mepivacaine—SCN8A—Developmental Biology—PSEN2—dilated cardiomyopathy	0.000264	0.00306	CbGpPWpGaD
Mepivacaine—Tachycardia—Lisinopril—dilated cardiomyopathy	0.000263	0.00997	CcSEcCtD
Mepivacaine—Hyperhidrosis—Lisinopril—dilated cardiomyopathy	0.00026	0.00987	CcSEcCtD
Mepivacaine—Asthenia—Furosemide—dilated cardiomyopathy	0.000258	0.00977	CcSEcCtD
Mepivacaine—Pruritus—Furosemide—dilated cardiomyopathy	0.000254	0.00963	CcSEcCtD
Mepivacaine—Hypotension—Lisinopril—dilated cardiomyopathy	0.000252	0.00954	CcSEcCtD
Mepivacaine—SCN5A—L1CAM interactions—RAC1—dilated cardiomyopathy	0.000248	0.00288	CbGpPWpGaD
Mepivacaine—Paraesthesia—Lisinopril—dilated cardiomyopathy	0.000242	0.00917	CcSEcCtD
Mepivacaine—Somnolence—Lisinopril—dilated cardiomyopathy	0.00024	0.00908	CcSEcCtD
Mepivacaine—Dizziness—Furosemide—dilated cardiomyopathy	0.000237	0.009	CcSEcCtD
Mepivacaine—SCN8A—Axon guidance—ITGB1—dilated cardiomyopathy	0.000231	0.00269	CbGpPWpGaD
Mepivacaine—Vomiting—Furosemide—dilated cardiomyopathy	0.000228	0.00865	CcSEcCtD
Mepivacaine—Headache—Furosemide—dilated cardiomyopathy	0.000225	0.00853	CcSEcCtD
Mepivacaine—SCN8A—L1CAM interactions—EGFR—dilated cardiomyopathy	0.000224	0.0026	CbGpPWpGaD
Mepivacaine—SCN5A—SIDS Susceptibility Pathways—GJA1—dilated cardiomyopathy	0.000221	0.00256	CbGpPWpGaD
Mepivacaine—Urticaria—Lisinopril—dilated cardiomyopathy	0.000214	0.00811	CcSEcCtD
Mepivacaine—SCN9A—Developmental Biology—PSEN2—dilated cardiomyopathy	0.000214	0.00248	CbGpPWpGaD
Mepivacaine—Nausea—Furosemide—dilated cardiomyopathy	0.000213	0.00808	CcSEcCtD
Mepivacaine—Body temperature increased—Lisinopril—dilated cardiomyopathy	0.000213	0.00807	CcSEcCtD
Mepivacaine—SCN3A—Developmental Biology—PSEN2—dilated cardiomyopathy	0.000204	0.00237	CbGpPWpGaD
Mepivacaine—Hypersensitivity—Lisinopril—dilated cardiomyopathy	0.000199	0.00752	CcSEcCtD
Mepivacaine—SCN2A—Developmental Biology—PSEN2—dilated cardiomyopathy	0.000196	0.00228	CbGpPWpGaD
Mepivacaine—SCN4A—Developmental Biology—PSEN2—dilated cardiomyopathy	0.000196	0.00228	CbGpPWpGaD
Mepivacaine—Asthenia—Lisinopril—dilated cardiomyopathy	0.000193	0.00733	CcSEcCtD
Mepivacaine—SCN5A—SIDS Susceptibility Pathways—IL10—dilated cardiomyopathy	0.000191	0.00222	CbGpPWpGaD
Mepivacaine—Pruritus—Lisinopril—dilated cardiomyopathy	0.000191	0.00723	CcSEcCtD
Mepivacaine—SCN1A—Developmental Biology—PSEN2—dilated cardiomyopathy	0.000189	0.0022	CbGpPWpGaD
Mepivacaine—SCN10A—Developmental Biology—PSEN2—dilated cardiomyopathy	0.000189	0.0022	CbGpPWpGaD
Mepivacaine—SCN9A—Axon guidance—ITGB1—dilated cardiomyopathy	0.000187	0.00217	CbGpPWpGaD
Mepivacaine—SCN5A—Axon guidance—PSEN2—dilated cardiomyopathy	0.000186	0.00216	CbGpPWpGaD
Mepivacaine—SCN8A—Axon guidance—RAC1—dilated cardiomyopathy	0.000186	0.00216	CbGpPWpGaD
Mepivacaine—SCN9A—L1CAM interactions—EGFR—dilated cardiomyopathy	0.000181	0.0021	CbGpPWpGaD
Mepivacaine—SCN3A—Axon guidance—ITGB1—dilated cardiomyopathy	0.000179	0.00208	CbGpPWpGaD
Mepivacaine—Dizziness—Lisinopril—dilated cardiomyopathy	0.000178	0.00675	CcSEcCtD
Mepivacaine—SCN3A—L1CAM interactions—EGFR—dilated cardiomyopathy	0.000173	0.00201	CbGpPWpGaD
Mepivacaine—SCN2A—Axon guidance—ITGB1—dilated cardiomyopathy	0.000172	0.002	CbGpPWpGaD
Mepivacaine—SCN4A—Axon guidance—ITGB1—dilated cardiomyopathy	0.000172	0.002	CbGpPWpGaD
Mepivacaine—Vomiting—Lisinopril—dilated cardiomyopathy	0.000171	0.00649	CcSEcCtD
Mepivacaine—Headache—Lisinopril—dilated cardiomyopathy	0.000169	0.0064	CcSEcCtD
Mepivacaine—SCN2A—L1CAM interactions—EGFR—dilated cardiomyopathy	0.000166	0.00193	CbGpPWpGaD
Mepivacaine—SCN4A—L1CAM interactions—EGFR—dilated cardiomyopathy	0.000166	0.00193	CbGpPWpGaD
Mepivacaine—SCN1A—Axon guidance—ITGB1—dilated cardiomyopathy	0.000166	0.00192	CbGpPWpGaD
Mepivacaine—SCN10A—Axon guidance—ITGB1—dilated cardiomyopathy	0.000166	0.00192	CbGpPWpGaD
Mepivacaine—SCN8A—Developmental Biology—ITGB1—dilated cardiomyopathy	0.000165	0.00192	CbGpPWpGaD
Mepivacaine—SCN1A—L1CAM interactions—EGFR—dilated cardiomyopathy	0.00016	0.00186	CbGpPWpGaD
Mepivacaine—SCN10A—L1CAM interactions—EGFR—dilated cardiomyopathy	0.00016	0.00186	CbGpPWpGaD
Mepivacaine—Nausea—Lisinopril—dilated cardiomyopathy	0.00016	0.00607	CcSEcCtD
Mepivacaine—SCN9A—Axon guidance—RAC1—dilated cardiomyopathy	0.00015	0.00175	CbGpPWpGaD
Mepivacaine—SCN3A—Axon guidance—RAC1—dilated cardiomyopathy	0.000144	0.00167	CbGpPWpGaD
Mepivacaine—SCN8A—Developmental Biology—CD36—dilated cardiomyopathy	0.000141	0.00163	CbGpPWpGaD
Mepivacaine—SCN4A—Axon guidance—RAC1—dilated cardiomyopathy	0.000138	0.0016	CbGpPWpGaD
Mepivacaine—SCN2A—Axon guidance—RAC1—dilated cardiomyopathy	0.000138	0.0016	CbGpPWpGaD
Mepivacaine—SCN9A—Developmental Biology—ITGB1—dilated cardiomyopathy	0.000134	0.00155	CbGpPWpGaD
Mepivacaine—SCN10A—Axon guidance—RAC1—dilated cardiomyopathy	0.000133	0.00155	CbGpPWpGaD
Mepivacaine—SCN1A—Axon guidance—RAC1—dilated cardiomyopathy	0.000133	0.00155	CbGpPWpGaD
Mepivacaine—SCN5A—Developmental Biology—PSEN2—dilated cardiomyopathy	0.000133	0.00154	CbGpPWpGaD
Mepivacaine—SCN8A—Developmental Biology—RAC1—dilated cardiomyopathy	0.000133	0.00154	CbGpPWpGaD
Mepivacaine—SCN3A—Developmental Biology—ITGB1—dilated cardiomyopathy	0.000128	0.00148	CbGpPWpGaD
Mepivacaine—SCN8A—Axon guidance—RAF1—dilated cardiomyopathy	0.000123	0.00143	CbGpPWpGaD
Mepivacaine—SCN2A—Developmental Biology—ITGB1—dilated cardiomyopathy	0.000123	0.00142	CbGpPWpGaD
Mepivacaine—SCN4A—Developmental Biology—ITGB1—dilated cardiomyopathy	0.000123	0.00142	CbGpPWpGaD
Mepivacaine—SCN1A—Developmental Biology—ITGB1—dilated cardiomyopathy	0.000118	0.00137	CbGpPWpGaD
Mepivacaine—SCN10A—Developmental Biology—ITGB1—dilated cardiomyopathy	0.000118	0.00137	CbGpPWpGaD
Mepivacaine—SCN5A—Axon guidance—ITGB1—dilated cardiomyopathy	0.000117	0.00135	CbGpPWpGaD
Mepivacaine—SCN9A—Developmental Biology—CD36—dilated cardiomyopathy	0.000114	0.00132	CbGpPWpGaD
Mepivacaine—SCN5A—L1CAM interactions—EGFR—dilated cardiomyopathy	0.000113	0.00131	CbGpPWpGaD
Mepivacaine—SCN3A—Developmental Biology—CD36—dilated cardiomyopathy	0.000109	0.00126	CbGpPWpGaD
Mepivacaine—SCN9A—Developmental Biology—RAC1—dilated cardiomyopathy	0.000107	0.00125	CbGpPWpGaD
Mepivacaine—SCN2A—Developmental Biology—CD36—dilated cardiomyopathy	0.000105	0.00121	CbGpPWpGaD
Mepivacaine—SCN4A—Developmental Biology—CD36—dilated cardiomyopathy	0.000105	0.00121	CbGpPWpGaD
Mepivacaine—SCN3A—Developmental Biology—RAC1—dilated cardiomyopathy	0.000103	0.00119	CbGpPWpGaD
Mepivacaine—SCN10A—Developmental Biology—CD36—dilated cardiomyopathy	0.000101	0.00117	CbGpPWpGaD
Mepivacaine—SCN1A—Developmental Biology—CD36—dilated cardiomyopathy	0.000101	0.00117	CbGpPWpGaD
Mepivacaine—SCN9A—Axon guidance—RAF1—dilated cardiomyopathy	9.98e-05	0.00116	CbGpPWpGaD
Mepivacaine—SCN4A—Developmental Biology—RAC1—dilated cardiomyopathy	9.87e-05	0.00114	CbGpPWpGaD
Mepivacaine—SCN2A—Developmental Biology—RAC1—dilated cardiomyopathy	9.87e-05	0.00114	CbGpPWpGaD
Mepivacaine—SCN3A—Axon guidance—RAF1—dilated cardiomyopathy	9.54e-05	0.00111	CbGpPWpGaD
Mepivacaine—SCN10A—Developmental Biology—RAC1—dilated cardiomyopathy	9.51e-05	0.0011	CbGpPWpGaD
Mepivacaine—SCN1A—Developmental Biology—RAC1—dilated cardiomyopathy	9.51e-05	0.0011	CbGpPWpGaD
Mepivacaine—SCN5A—Axon guidance—RAC1—dilated cardiomyopathy	9.37e-05	0.00109	CbGpPWpGaD
Mepivacaine—SCN2A—Axon guidance—RAF1—dilated cardiomyopathy	9.17e-05	0.00106	CbGpPWpGaD
Mepivacaine—SCN4A—Axon guidance—RAF1—dilated cardiomyopathy	9.17e-05	0.00106	CbGpPWpGaD
Mepivacaine—SCN10A—Axon guidance—RAF1—dilated cardiomyopathy	8.84e-05	0.00103	CbGpPWpGaD
Mepivacaine—SCN1A—Axon guidance—RAF1—dilated cardiomyopathy	8.84e-05	0.00103	CbGpPWpGaD
Mepivacaine—SCN8A—Developmental Biology—RAF1—dilated cardiomyopathy	8.8e-05	0.00102	CbGpPWpGaD
Mepivacaine—SCN8A—Axon guidance—EGFR—dilated cardiomyopathy	8.46e-05	0.000982	CbGpPWpGaD
Mepivacaine—SCN5A—Developmental Biology—ITGB1—dilated cardiomyopathy	8.32e-05	0.000966	CbGpPWpGaD
Mepivacaine—SCN5A—SIDS Susceptibility Pathways—TNF—dilated cardiomyopathy	7.28e-05	0.000845	CbGpPWpGaD
Mepivacaine—SCN9A—Developmental Biology—RAF1—dilated cardiomyopathy	7.12e-05	0.000826	CbGpPWpGaD
Mepivacaine—SCN5A—Developmental Biology—CD36—dilated cardiomyopathy	7.1e-05	0.000824	CbGpPWpGaD
Mepivacaine—SCN9A—Axon guidance—EGFR—dilated cardiomyopathy	6.84e-05	0.000794	CbGpPWpGaD
Mepivacaine—SCN3A—Developmental Biology—RAF1—dilated cardiomyopathy	6.81e-05	0.00079	CbGpPWpGaD
Mepivacaine—SCN5A—Developmental Biology—RAC1—dilated cardiomyopathy	6.69e-05	0.000776	CbGpPWpGaD
Mepivacaine—SCN3A—Axon guidance—EGFR—dilated cardiomyopathy	6.54e-05	0.000759	CbGpPWpGaD
Mepivacaine—SCN2A—Developmental Biology—RAF1—dilated cardiomyopathy	6.54e-05	0.000759	CbGpPWpGaD
Mepivacaine—SCN4A—Developmental Biology—RAF1—dilated cardiomyopathy	6.54e-05	0.000759	CbGpPWpGaD
Mepivacaine—SCN1A—Developmental Biology—RAF1—dilated cardiomyopathy	6.31e-05	0.000732	CbGpPWpGaD
Mepivacaine—SCN10A—Developmental Biology—RAF1—dilated cardiomyopathy	6.31e-05	0.000732	CbGpPWpGaD
Mepivacaine—SCN2A—Axon guidance—EGFR—dilated cardiomyopathy	6.29e-05	0.00073	CbGpPWpGaD
Mepivacaine—SCN4A—Axon guidance—EGFR—dilated cardiomyopathy	6.29e-05	0.00073	CbGpPWpGaD
Mepivacaine—SCN5A—Axon guidance—RAF1—dilated cardiomyopathy	6.21e-05	0.000721	CbGpPWpGaD
Mepivacaine—SCN1A—Axon guidance—EGFR—dilated cardiomyopathy	6.06e-05	0.000703	CbGpPWpGaD
Mepivacaine—SCN10A—Axon guidance—EGFR—dilated cardiomyopathy	6.06e-05	0.000703	CbGpPWpGaD
Mepivacaine—SCN8A—Developmental Biology—EGFR—dilated cardiomyopathy	6.04e-05	0.0007	CbGpPWpGaD
Mepivacaine—SCN8A—Developmental Biology—TNF—dilated cardiomyopathy	5.75e-05	0.000667	CbGpPWpGaD
Mepivacaine—SCN9A—Developmental Biology—EGFR—dilated cardiomyopathy	4.88e-05	0.000566	CbGpPWpGaD
Mepivacaine—SCN3A—Developmental Biology—EGFR—dilated cardiomyopathy	4.67e-05	0.000542	CbGpPWpGaD
Mepivacaine—SCN9A—Developmental Biology—TNF—dilated cardiomyopathy	4.65e-05	0.00054	CbGpPWpGaD
Mepivacaine—SCN2A—Developmental Biology—EGFR—dilated cardiomyopathy	4.49e-05	0.000521	CbGpPWpGaD
Mepivacaine—SCN4A—Developmental Biology—EGFR—dilated cardiomyopathy	4.49e-05	0.000521	CbGpPWpGaD
Mepivacaine—SCN3A—Developmental Biology—TNF—dilated cardiomyopathy	4.45e-05	0.000516	CbGpPWpGaD
Mepivacaine—SCN5A—Developmental Biology—RAF1—dilated cardiomyopathy	4.44e-05	0.000515	CbGpPWpGaD
Mepivacaine—SCN10A—Developmental Biology—EGFR—dilated cardiomyopathy	4.33e-05	0.000502	CbGpPWpGaD
Mepivacaine—SCN1A—Developmental Biology—EGFR—dilated cardiomyopathy	4.33e-05	0.000502	CbGpPWpGaD
Mepivacaine—SCN2A—Developmental Biology—TNF—dilated cardiomyopathy	4.27e-05	0.000496	CbGpPWpGaD
Mepivacaine—SCN4A—Developmental Biology—TNF—dilated cardiomyopathy	4.27e-05	0.000496	CbGpPWpGaD
Mepivacaine—SCN5A—Axon guidance—EGFR—dilated cardiomyopathy	4.26e-05	0.000495	CbGpPWpGaD
Mepivacaine—SCN10A—Developmental Biology—TNF—dilated cardiomyopathy	4.12e-05	0.000478	CbGpPWpGaD
Mepivacaine—SCN1A—Developmental Biology—TNF—dilated cardiomyopathy	4.12e-05	0.000478	CbGpPWpGaD
Mepivacaine—SCN5A—Developmental Biology—EGFR—dilated cardiomyopathy	3.04e-05	0.000353	CbGpPWpGaD
Mepivacaine—SCN5A—Developmental Biology—TNF—dilated cardiomyopathy	2.9e-05	0.000336	CbGpPWpGaD
